Damian Garde is a reporter for STAT, a leading health and science publication. His articles cover a wide range of topics in the biotech industry, including trends, company news, FDA approvals, and healthcare conferences. Damian's work has also been featured in the Boston Globe Technology section.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Damian Garde's coverage predominantly focuses on the healthcare and pharmaceutical industries, particularly biotechnology. He frequently cites data and press releases while also incorporating expert commentary.
To effectively engage Damian, offer insights backed by relevant data or provide access to industry experts who can offer nuanced perspectives on developments within the biotech, healthcare, and pharmaceutical sectors. Considering his focus on specific companies and deals, pitches should involve sources with direct knowledge of the events covered or deep expertise in similar occurrences within these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Damian Garde, Jef Feeley
Johnson & Johnson was twice blocked in New Jersey from getting bankruptcy protection from one of its units to resolve billions of dollars in cancer claims tied to baby powder use. For its third try, the company is eyeing Texas, home to what are widely considered more business-friendly courts.
Hello, everyone. It’s Damian in New York. If you, like me, feel suddenly inundated with content about the allegedly transformational power of hypnotherapy, I have done some work for us. But first ...
Ein Kombi-Impfstoffkandidat von BioNTech und Pfizer gegen Grippe und Covid-19 hat in der Endphase-Studie eines seiner Ziele verfehlt. Ein Rückschlag für die Unternehmen, die nach neuen lukrativen Anwendungen für ihre bei der Pandemie bewährten Technologien suchen.
US teenagers aren't getting vaccinated against HPV at the same pace as before the Covid pandemic, a trend that could imperil efforts to control a common cause of cervical and other cancers.
Struggling with plunging demand for its Covid products, Pfizer Inc. has a new plan to reach potential customers: Cutting out middleman and selling drugs straight to patients.
Struggling with plunging demand for its Covid products, Pfizer Inc. has a new plan to reach potential customers: Cutting out middleman and selling drugs straight to patients.
By: Damian Garde
Struggling with plunging demand for its Covid products, Pfizer Inc. has a new plan to reach potential customers: Cutting out middleman and selling drugs straight to patients.
Hi, everyone! Damian here in New York. The latest news on blockbuster weight-loss drugs has led to some understandable head-scratching among pharma-watchers. But first …
By: Damian Garde, Gerry Smith
Neurocrine Biosciences Inc. 's experimental schizophrenia treatment met the goal of a mid-stage trial. The shares fell as investors were disappointed in the results compared with those of a rival medicine in development.
By: Damian Garde, Gerry Smith
Neurocrine Biosciences Inc. plunged early Wednesday after a study of its experimental schizophrenia treatment was disappointing when compared to a rival medicine that's likely to hit the market much sooner.
(833) 317-6278 
